Association of Single Nucleotide Polymorphisms in STAT3 with Hand-Foot Skin Reactions in Patients with Metastatic Renal Cell Carcinoma Treated with Multiple Tyrosine Kinase Inhibitors: A Retrospective Analysis in Japanese Patients

[1]  M. Tan,et al.  Association of drug exposure with toxicity and clinical response in metastatic renal cell carcinoma patients receiving an attenuated dosing regimen of sunitinib , 2015, Targeted Oncology.

[2]  A. Kawauchi,et al.  Assessment of Sunitinib-Induced Toxicities and Clinical Outcomes Based on Therapeutic Drug Monitoring of Sunitinib for Patients With Renal Cell Carcinoma. , 2015, Clinical genitourinary cancer.

[3]  K. Inui,et al.  Management of dose variability and side effects for individualized cancer pharmacotherapy with tyrosine kinase inhibitors. , 2015, Pharmacology & therapeutics.

[4]  S. Akira,et al.  STAT3-dependent reactive astrogliosis in the spinal dorsal horn underlies chronic itch , 2015, Nature Medicine.

[5]  C. Watson,et al.  STAT3 the oncogene – still eluding therapy? , 2015, The FEBS journal.

[6]  M. Tan,et al.  Effect of the CYP3A5 and ABCB1 genotype on exposure, clinical response and manifestation of toxicities from sunitinib in Asian patients , 2015, The Pharmacogenomics Journal.

[7]  C. Porta,et al.  PD-1 blockade therapy in renal cell carcinoma: current studies and future promises. , 2015, Cancer treatment reviews.

[8]  S. Stylli,et al.  The role of STAT3 signaling in mediating tumor resistance to cancer therapy. , 2014, Current drug targets.

[9]  M. Hirai,et al.  Association of Toxicity of Sorafenib and Sunitinib for Human Keratinocytes with Inhibition of Signal Transduction and Activator of Transcription 3 (STAT3) , 2014, PloS one.

[10]  Qiang Xu,et al.  Axitinib augments antitumor activity in renal cell carcinoma via STAT3-dependent reversal of myeloid-derived suppressor cell accumulation. , 2014, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[11]  Junjiang Fu,et al.  Epithelial to mesenchymal transition inducing transcription factors and metastatic cancer , 2014, Tumor Biology.

[12]  T. Yamasaki,et al.  The Effect of ABCG2 Genotype on the Population Pharmacokinetics of Sunitinib in Patients With Renal Cell Carcinoma , 2014, Therapeutic drug monitoring.

[13]  Michael K. Wendt,et al.  STAT3 and epithelial–mesenchymal transitions in carcinomas , 2014, JAK-STAT.

[14]  G. Park,et al.  ROS-mediated JNK/p38-MAPK activation regulates Bax translocation in Sorafenib-induced apoptosis of EBV-transformed B cells. , 2014, International journal of oncology.

[15]  T. Yamasaki,et al.  Exposure–Toxicity Relationship of Sorafenib in Japanese Patients with Renal Cell Carcinoma and Hepatocellular Carcinoma , 2014, Clinical Pharmacokinetics.

[16]  Y. Kluger,et al.  PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases , 2014, Journal of Cancer.

[17]  S. Sano,et al.  Epidermal hyperplasia induced by Raf-MAPK signaling requires Stat3 activation. , 2013, Journal of dermatological science.

[18]  M. Hirai,et al.  Everolimus-induced human keratinocytes toxicity is mediated by STAT3 inhibition , 2013, Journal of experimental & clinical cancer research : CR.

[19]  M. Terencio,et al.  NF-κB and STAT3 inhibition as a therapeutic strategy in psoriasis: in vitro and in vivo effects of BTH. , 2013, The Journal of investigative dermatology.

[20]  Todd A. Johnson,et al.  A genome-wide association study identifies 2 susceptibility Loci for Crohn's disease in a Japanese population. , 2013, Gastroenterology.

[21]  H. Miyake,et al.  STAT3 polymorphism can predict the response to interferon-α therapy in patients with metastatic renal cell carcinoma. , 2013, European Urology.

[22]  T. Habuchi,et al.  Risk factors for sorafenib-induced high-grade skin rash in Japanese patients with advanced renal cell carcinoma , 2013, Anti-cancer drugs.

[23]  M. Lacouture,et al.  The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis , 2013, Investigational New Drugs.

[24]  J. Larkin,et al.  Second-line treatments for the management of advanced renal cell carcinoma: systematic review and meta-analysis , 2013, Expert opinion on pharmacotherapy.

[25]  Y. Kanda,et al.  Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.

[26]  A. Poprach,et al.  Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  D. Kass,et al.  Sunitinib causes dose‐dependent negative functional effects on myocardium and cardiomyocytes , 2012, BJU international.

[28]  S. Barni,et al.  Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials. , 2012, Lung cancer.

[29]  Y. Ko,et al.  Mechanistic correlations between two itch biomarkers, cytokine interleukin‐31 and neuropeptide β‐endorphin, via STAT3/calcium axis in atopic dermatitis , 2012, The British journal of dermatology.

[30]  O. Mir,et al.  Sorafenib-Induced Hepatocellular Carcinoma Cell Death Depends on Reactive Oxygen Species Production In Vitro and In Vivo , 2012, Molecular Cancer Therapeutics.

[31]  M. Loriot,et al.  Early Sorafenib-Induced Toxicity Is Associated with Drug Exposure and UGTIA9 Genetic Polymorphism in Patients with Solid Tumors: A Preliminary Study , 2012, PloS one.

[32]  H. Kung,et al.  Simultaneous targeting of Src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration , 2012, International journal of cancer.

[33]  J. Williams,et al.  Meta-analysis of contribution of genetic polymorphisms in drug-metabolizing enzymes or transporters to axitinib pharmacokinetics , 2012, European Journal of Clinical Pharmacology.

[34]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[35]  J. Patard,et al.  Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy? , 2012, European urology.

[36]  M. Hirai,et al.  Role of the mTOR complex 1 pathway in the in vivo maintenance of the intestinal mucosa by oral intake of amino acids , 2012, Geriatrics & gerontology international.

[37]  Yun Cui,et al.  Roles of STAT3 and ZEB1 Proteins in E-cadherin Down-regulation and Human Colorectal Cancer Epithelial-Mesenchymal Transition* , 2011, The Journal of Biological Chemistry.

[38]  J. Ptacek,et al.  Signal transducer and activator of transcription 3 (STAT3) and survivin induction by varicella-zoster virus promote replication and skin pathogenesis , 2011, Proceedings of the National Academy of Sciences.

[39]  Kuen-Feng Chen,et al.  Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma. , 2011, Journal of hepatology.

[40]  J. Furuse,et al.  Sorafenib‐associated hand–foot syndrome in Japanese patients , 2011, The Journal of dermatology.

[41]  M. Yoshikawa,et al.  Safety and tolerance of sorafenib in Japanese patients with advanced hepatocellular carcinoma , 2011, Hepatology international.

[42]  H. Guchelaar,et al.  Genetic Polymorphisms Associated with a Prolonged Progression-Free Survival in Patients with Metastatic Renal Cell Cancer Treated with Sunitinib , 2010, Clinical Cancer Research.

[43]  Kuen-Feng Chen,et al.  Sorafenib Overcomes TRAIL Resistance of Hepatocellular Carcinoma Cells through the Inhibition of STAT3 , 2010, Clinical Cancer Research.

[44]  G. Demetri,et al.  Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis , 2010, Cancer Chemotherapy and Pharmacology.

[45]  T. Putoczki,et al.  ReviewStat 3 : linking inflammation to epithelial cancer-more than a " gut " feeling ? , 2015 .

[46]  T. Miki,et al.  A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety. , 2010, Japanese journal of clinical oncology.

[47]  G. Tisman,et al.  Sorafenib-associated remission of psoriasis in hypernephroma: case report. , 2010, Dermatology online journal.

[48]  M. Sticherling,et al.  Cutaneous side effects of inhibition of VEGF signal transduction , 2009, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[49]  S. Kondo,et al.  Strong Evidence of a Combination Polymorphism of the Tyrosine Kinase 2 Gene and the Signal Transducer and Activator of Transcription 3 Gene as a DNA-Based Biomarker for Susceptibility to Crohn’s Disease in the Japanese Population , 2009, Journal of Clinical Immunology.

[50]  B. Aggarwal,et al.  Signal Transducer and Activator of Transcription‐3, Inflammation, and Cancer , 2009, Annals of the New York Academy of Sciences.

[51]  Xin Huang,et al.  Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  R. Figlin,et al.  Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. , 2009, Cancer research.

[53]  D. Levy,et al.  Activation of Stat3 in renal tumors. , 2009, American journal of translational research.

[54]  M. Wasik,et al.  Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1) , 2008, Proceedings of the National Academy of Sciences.

[55]  H. Kong,et al.  Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. , 2008, The oncologist.

[56]  Shigetoshi Sano,et al.  Impact of Stat3 activation upon skin biology: a dichotomy of its role between homeostasis and diseases. , 2008, Journal of dermatological science.

[57]  S. Pang,et al.  Hand‐foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy , 2007, The British journal of dermatology.

[58]  T. Uchida,et al.  Pin1 is required for the Ser727 phosphorylation-dependent Stat3 activity , 2007, Oncogene.

[59]  W. Gerald,et al.  Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. , 2007, The Journal of clinical investigation.

[60]  C. Porta,et al.  Uncovering Pandora’s vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib , 2007, Clinical and Experimental Medicine.

[61]  Naoko Kinukawa,et al.  STAT3 polymorphism predicts interferon-alfa response in patients with metastatic renal cell carcinoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  R. Thompson,et al.  Implications of B7-H1 Expression in Clear Cell Carcinoma of the Kidney for Prognostication and Therapy , 2007, Clinical Cancer Research.

[63]  Apurva A Desai,et al.  Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.

[64]  R. Figlin,et al.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.

[65]  F. Fantini,et al.  Survivin Identifies Keratinocyte Stem Cells and Is Downregulated by Anti‐β1 Integrin During Anoikis , 2007, Stem cells.

[66]  G. Rosner,et al.  Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  M. Santoro,et al.  BAY 43-9006 inhibition of oncogenic RET mutants. , 2006, Journal of the National Cancer Institute.

[68]  Hua Yu,et al.  Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity , 2005, Nature Medicine.

[69]  D. Auclair,et al.  BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.

[70]  U. Rodeck,et al.  Complex Regulation of Signal Transducers and Activators of Transcription 3 Activation in Normal and Malignant Keratinocytes , 2004, Cancer Research.

[71]  Hua Yu,et al.  The STATs of cancer — new molecular targets come of age , 2004, Nature Reviews Cancer.

[72]  Y. Wong,et al.  Constitutively Active Gα16 Stimulates STAT3 via a c-Src/JAK- and ERK-dependent Mechanism* , 2003, Journal of Biological Chemistry.

[73]  G. Feldman,et al.  Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. , 2003, Blood.

[74]  P. Real,et al.  Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells , 2002, Oncogene.

[75]  J. Darnell,et al.  Signalling: STATs: transcriptional control and biological impact , 2002, Nature Reviews Molecular Cell Biology.

[76]  M. Oya,et al.  Activation of signal transducer and activator of transcription 3 in renal cell carcinoma: a study of incidence and its association with pathological features and clinical outcome. , 2002, The Journal of urology.

[77]  J. Turkson,et al.  Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. , 2001, The Journal of clinical investigation.

[78]  D. Latchman,et al.  Opposing actions of STAT-1 and STAT-3 on the Bcl-2 and Bcl-x promoters , 2000, Cell Death and Differentiation.

[79]  A. Marconi,et al.  Autocrine nerve growth factor in human keratinocytes. , 2000, Journal of dermatological science.

[80]  Xinmin Cao,et al.  Serine Phosphorylation and Negative Regulation of Stat3 by JNK* , 1999, The Journal of Biological Chemistry.

[81]  J. Darnell,et al.  Stat3 as an Oncogene , 1999, Cell.

[82]  Shizuo Akira,et al.  Functional Roles of STAT Family Proteins: Lessons from Knockout Mice , 1999, Stem cells.

[83]  J. Darnell.  STATs and gene regulation. , 1997, Science.

[84]  J. Hornung,et al.  Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line , 1988, The Journal of cell biology.

[85]  Jiayuh Lin,et al.  Feedback Activation of STAT3 as a Cancer Drug-Resistance Mechanism. , 2016, Trends in pharmacological sciences.

[86]  M. Atkins,et al.  New agents and new targets for renal cell carcinoma. , 2014, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[87]  A. Marconi,et al.  Survivin: a dual player in healthy and diseased skin. , 2012, The Journal of investigative dermatology.

[88]  S. Bhambri.  Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib , 2011 .

[89]  三好 研.  Stat3 as a therapeutic target for the treatment of psoriasis : a clinical feasibility study with STA-21, a Stat3 inhibitor , 2010 .

[90]  Yoon-Koo Kang,et al.  Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. , 2009, The Lancet. Oncology.

[91]  P. Mischel,et al.  Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma , 2007, Nature Medicine.

[92]  R. Figlin,et al.  Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[93]  J. Clifford,et al.  Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model , 2005, Nature Medicine.

[94]  R. Motzer,et al.  Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.